跳至主要内容
临床试验/IRCT20190325043111N1
IRCT20190325043111N1已完成2 期

The effect of two different doses of Alendronate on the treatment of osteopenia based on fracture risk assessment (FRAX) in menopauses women who referred to Alzahra hospital during 2014-17

Esfahan University of Medical Sciences0 个研究点目标入组 140 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
140

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
45 years 至 no limit(—)
性别
Female

入选标准

  • Menopausal state
  • Osteopenia (hip or spine T-score -2.5 to -1)
  • Normal serum levels of vitamin D, Calcium, Phosphorus, Alkaline phosphatase
  • Lacking history of pathological or traumatic fractures
  • Lacking the diagnosis of malignancy

排除标准

  • The impossibility to determine FRAX index due to any reason
  • Osteoprosis (T-score worse than -2.5)
  • Osteopenia (hip or spine T-score -2.5 to -1) plus pathological fracture

研究者

相似试验

Assessment of two doses of Alendronate on the... | 临床试验